Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 17;12(17):1729-1733.
doi: 10.18632/oncotarget.28023.

Hypofractionation: less is more?

Neethu Billy Graham Mariam  1 , Yee Pei Song  1   2 , Nuradh Joseph  3 , Peter Hoskin  2   4 , Kimberley Reeves  2 , Nuria Porta  5 , Nicholas James  6 , Ananya Choudhury  1   2
Affiliations

Hypofractionation: less is more?

Neethu Billy Graham Mariam et al. Oncotarget. .

Abstract

One third of patients with bladder cancer present with muscle invasive bladder cancer (MIBC) which has a poor prognosis. International guidelines for the management of MIBC recommend radical cystectomy or bladder-preserving treatment based on radical radiotherapy with a form of radiosensitisation. In the UK, both conventional fractionation with 64 Gy in 32 fractions and hypofractionation with 55 Gy in 20 fractions are standard of care options with the choice varying between centres. A meta-analysis of individual patients with locally advanced bladder cancer from two UK multicentre phase 3 trials was published recently. This study evaluated the non-inferiority of a hypofractionated schedule compared to a conventional regime. This analysis confirmed the non-inferiority of the hypofractionated regimen, and noted superior locoregional control. We discuss the relevance of these findings to current practice while considering the radiobiology of hypofractionation, the role of systemic therapies and radiosensitisation, as well as the socioeconomic benefits.

Keywords: BC2001; BCON; bladder cancer; hypofractionation.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST Yee Pei Song: Bayer - Honorarium, Merck Serono - Advisory board.

References

    1. Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, West CML, Lewis R, Hussain SA, James ND, Huddart R, Hoskin P, and BC2001 and BCON investigators. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021; 22:246–55. 10.1016/S1470-2045(20)30607-0. - DOI - PMC - PubMed
    1. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, and BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366:1477–88. 10.1056/NEJMoa1106106. - DOI - PubMed
    1. Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, Crundwell M, Adab FA, Sheehan D, Syndikus I, Hendron C, Lewis R, Waters R, James ND. Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int J Radiat Oncol Biol Phys. 2013; 87:261–69. 10.1016/j.ijrobp.2013.06.2044. - DOI - PMC - PubMed
    1. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. 2010; 28:4912–18. 10.1200/JCO.2010.28.4950. - DOI - PubMed
    1. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (Basel). 2020; 8:15. 10.3390/medsci8010015. - DOI - PMC - PubMed